US Executive Compensation Proxy SEC Filings — April 24, 2026

24-04-2026

Kalaris Therapeutics, Inc. (KLRS), formerly AlloVir, Inc., issued its DEF 14A proxy statement dated April 24, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 3, 2026 (record date April 6, 2026), following its merger with Legacy Kalaris Tx, Inc. on March 18, 2025 and a 1-for-23 reverse stock split effective January 15, 2025. Proposals include the election of three Class III directors (Napoleone Ferrara, M.D., David Hallal, Leone Patterson), an advisory vote to approve executive compensation, an advisory vote on the frequency of future say-on-pay votes, and ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. The statement covers board governance, director independence, executive and director compensation disclosures (including pay versus performance for 2024-2025), and related-party transactions.

• ·Annual Meeting exclusively virtual at www.proxydocs.com/KLRS, 11:30 a.m. Eastern Time
• ·Proxy materials and 2025 Annual Report available at www.proxydocs.com/KLRS; paper requests due by May 22, 2026
• ·Merger Agreement dated November 7, 2024
• ·Company address: 400 Connell Drive, Suite 5500, Berkeley Heights, New Jersey 07922; phone (650) 249-2727

24-04-2026

Enovix Corporation's 2026 Proxy Statement discloses non-employee director compensation for fiscal year 2025, including annual cash retainers starting at $50,000 plus committee fees, initial RSU awards valued at $275,000, and annual RSU awards valued at approximately $195,000. Total compensation ranged from $259,997 to $458,886 across directors, with all receiving RSU grants on June 12, 2025, except J. Daniel McCranie who received initial and pro-rated awards. The filing also provides company overview on silicon-anode batteries, AI-1 platform, manufacturing in Asia, and 2025 sustainability highlights including certifications and policy adoptions.

• ·Fiscal year ended December 28, 2025.
• ·Proxy filed April 24, 2026.
• ·Sustainability Report published April 22, 2025.
• ·RSU awards vest quarterly; annual awards fully vest within one year or at next stockholder meeting.
• ·Equity awards accelerate fully upon Change of Control.
• ·Non-employee directors reimbursed for travel expenses.
• ·Insider trading policy prohibits short sales, options, hedging, pledges without approval; Mr. Rodgers received waiver for collateral use.

24-04-2026

Nasdaq's 2026 Proxy Statement recaps exceptional 2025 performance, surpassing $5.2 billion in annual net revenue and $4 billion in Solutions revenue for the first time, achieving record Index AUM of $882 billion with $99 billion net inflows, record U.S. equities and options revenues, and $1.2 trillion in listing transfers while maintaining #1 U.S. listing exchange position. The company reported 14% growth in Financial Technology revenue and ARR, increased quarterly dividend by 13% to $0.27 per share, repaid $826 million in debt ahead of schedule, and returned over $1.2 billion to shareholders through dividends and repurchases. Adenza acquisition became EPS accretive six months ahead of target, with innovations like tokenized equity securities and 23/5 trading approved.

• ·Nasdaq maintained #1 U.S. listing exchange by proceeds raised for seventh straight year.
• ·Adenza acquisition became EPS accretive in Q3 2025, less than 18 months post-closing and six months ahead of target.
• ·Earned credit rating upgrades from Moody’s and S&P in 2025.
• ·Serves approximately 3,800 financial institutions and 135 markets and regulators.

24-04-2026

Consensus Cloud Solutions, Inc. (CCSI) has filed a DEF 14A proxy statement for its annual shareholder meeting on June 10, 2026, seeking approval for the election of six directors (five independent), ratification of the independent auditor, an advisory vote on named executive officer compensation, and an amendment to increase authorized shares under the stock incentive plan. The proxy highlights the company's evolution from cloud fax (eFax®) to secure information exchange solutions for regulated industries like healthcare and public sector, emphasizing strengths such as HITRUST and FedRAMP certifications, 67% monthly recurring subscription revenue, and a diversified global customer base. Corporate governance features include an independent Chairman, majority independent board, and prohibitions on hedging/pledging.

• ·Record date: April 13, 2026
• ·Annual meeting: June 10, 2026 at 8:30 a.m. Pacific Time, online at www.virtualshareholdermeeting.com/CCSI2026
• ·Spin-off completion date: October 7, 2021
• ·Board committees: Audit (AC), Compensation (CC), ESG, Executive (EXE); key roles held by independents
• ·Director ages: Douglas Bech (80), Elaine Healy (63), Stephen Ross (78), Nathaniel Simmons (49), Pamela Sutton-Wallace (56), Scott Turicchi (62)

24-04-2026

Adaptive Biotechnologies reported 2025 revenue of $277.0 million, up 55% YoY from $179.0 million in 2024, driven by MRD revenue of $212.3 million (+46% YoY) and clonoSEQ test volume growth of 39% to 105,587 tests. Net cash used in operations improved 52% to $46.0 million from $95.2 million, with cash and equivalents at $227.2 million as of December 31, 2025. However, the company discontinued investments in its TCR-depleting antibody program for ankylosing spondylitis to focus on data and diagnostics.

• ·Payor coverage expanded to over 300 million lives in B cell acute lymphoblastic leukemia and multiple myeloma, over 270 million in chronic lymphocytic leukemia, and over 90 million in diffuse large B cell lymphoma; Medicare coverage for recurrence monitoring in mantle cell lymphoma.
• ·clonoSEQ enabled in 173 sites on Epic EMR, through Flatiron OncoEMR, and other EMRs.
• ·Over 100 trials use MRD as clinical endpoint (19 primary); paired TCRs increased to over 5 million across over 20,000 antigens and nearly 50 HLA types.
• ·Entered non-exclusive agreements with Pfizer in December 2025 for TCR platform in rheumatoid arthritis and immunology.
• ·Received B rating from CDP in climate and Silver rating from Ecovadis.

24-04-2026

Procore Technologies, Inc. filed its DEF 14A Proxy Statement dated April 24, 2026, for the 2026 Annual Meeting of Stockholders on June 4, 2026, seeking election of Class II directors for terms expiring in 2029, ratification of the independent auditor, and an advisory vote to approve named executive officer compensation. The proxy highlights robust corporate governance with a separate Board Chair and CEO, 100% independent committees, 36% female directors, and 27% ethnically diverse directors; executive compensation emphasizes performance-based PSUs (50% of CEO equity mix) and received 83% Say on Pay approval at the 2025 meeting. Business overview notes Procore's platform has supported over three million projects across more than 150 countries, with CEO transition from Mr. Courtemanche to Dr. Gopal, including $0.5M one-time bonus and $3.0M PSU grant to the former CEO.

• ·Annual Meeting: June 4, 2026, 9:00 a.m. Pacific Time, virtual at www.proxydocs.com/PCOR
• ·Record Date: April 10, 2026
• ·Dr. Gopal target bonus opportunity: 150% of base salary for 2026 Bonus Program
• ·PSU equity mix for non-CEO executives in 2026: 40%

24-04-2026

Palantir Technologies Inc. filed its DEF 14A proxy statement on April 24, 2026, for the virtual annual stockholder meeting on June 3, 2026, at 10:00 a.m. ET, with record date April 6, 2026. Key votes include electing seven directors, ratifying Ernst & Young LLP as auditors for fiscal year ending December 31, 2026, and an advisory approval of named executive officer compensation; three stockholder proposals on due diligence reporting, human rights impact assessments, and political spending disclosure are also included, though the board opposes them. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual meeting held virtually at www.virtualshareholdermeeting.com/PLTR2026
• ·Proxy materials available at www.proxyvote.com as of April 24, 2026
• ·Corporate headquarters: 19505 Biscayne Boulevard, Suite 2350, Aventura, Florida 33180
• ·Board opposes Stockholder Proposals No. 4 (due diligence report), No. 5 (human rights assessment), and No. 6 (political spending disclosure)

24-04-2026

Vaalco Energy, Inc. seeks shareholder approval at its 2026 Annual Meeting to elect five incumbent director nominees—Andrew L. Fawthrop (Chairman), George W. M. Maxwell (CEO), Cathy Stubbs, Fabrice Nze-Bekale, and Edward LaFehr—for terms expiring at the 2027 Annual Meeting. The Board, which nominated them on March 12, 2026, confirms a majority independent structure (4 out of 5 independent) and unanimously recommends voting 'FOR' all nominees under a plurality voting standard. No arrangements or understandings govern the nominations, and the Board has no reason to believe any nominee will decline service.

• ·Director tenures: Fawthrop (since 2014), Maxwell (since 2020), Stubbs (since 2020), Nze-Bekale (since 2022), LaFehr (since 2022).
• ·Shareholder list available for examination 10 days prior to Annual Meeting at Houston offices.
• ·Broker non-votes and withhold votes have no effect on director election outcome.
• ·Filing date: April 24, 2026

24-04-2026

Acadia Pharmaceuticals Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on May 29, 2026 at 8:00 a.m. PT. Proposals include electing three Class I directors to serve until the 2029 annual meeting, advisory approval of named executive officer compensation, ratification of Ernst & Young LLP as independent auditors for FY 2026, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 5,209,670. The record date is April 14, 2026, with 171,215,262 shares of common stock outstanding.

• ·Virtual meeting access: meetnow.global/MGYT5K7; login from 7:45 a.m. PT on May 29, 2026.
• ·Proxy materials mailed on or about April 28, 2026.
• ·Legal proxy registration deadline: 5:00 p.m. ET on May 26, 2026.

24-04-2026

Live Nation Entertainment, Inc.'s DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders on June 11, 2026, seeks approval for electing 12 director nominees, an advisory vote on executive compensation, and ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. 2025 financial highlights show revenue of $25.2B, operating income of $1.3B, and AOI of $2.4B, reflecting strong performance with no declines noted. The board recommends voting FOR all three proposals.

• ·Annual Meeting: June 11, 2026 at 9:00 a.m. PDT, 9348 Civic Center Drive, Beverly Hills, California 90210
• ·Record Date: April 13, 2026
• ·Proxy materials available on internet via www.proxydocs.com/LYV; Notice of Availability mailed on or about April 24, 2026

24-04-2026

GoDaddy Inc.'s 2026 Proxy Statement highlights robust 2025 financial performance, including net income of $875.0 million (17.7% margin), normalized EBITDA over $1.6 billion (32% margin with over 1,000 basis points expansion in five years), net cash from operating activities of $1.6 billion, and free cash flow of $1.6 billion up 19% YoY, enabling repurchase of 10.2 million shares. The virtual annual meeting is scheduled for June 3, 2026, with proposals for electing nine directors, advisory approval of NEO compensation, ratification of Ernst & Young LLP as auditors, and approval of the Amended and Restated 2024 Omnibus Incentive Plan. The Board Chair emphasizes AI advancements like Agent Name Service (ANS) and Agentic Open Internet amid no reported declines.

• ·Record date for annual meeting: April 6, 2026
• ·Annual meeting date and time: June 3, 2026, 8:00 a.m. PDT (virtual at www.virtualshareholdermeeting.com/GDDY2026)
• ·Nine director nominees for election
• ·NEBITDA margin expanded more than 1,000 basis points over past five years

24-04-2026

OPENLANE's DEF 14A proxy statement for the June 5, 2026 virtual annual meeting proposes electing nine directors (one Apax designee and eight others), advisory approval of executive compensation, and ratification of KPMG LLP as auditors for 2026, with the Board recommending FOR all. FY2025 highlights show revenue up 8% to $1.9 billion, operating profit up 8% to $196.6 million, cash flow from operations up 34% to $391.9 million, and dealer volumes up 15%, while vehicles sold grew modestly 2% to 1.47 million with ~$29 billion GMV (all continuing operations). The Board emphasizes strong governance, including 8/9 independent nominees, annual elections, majority voting, and robust equity ownership requirements.

• ·Annual meeting: June 5, 2026, 9:00 a.m. EDT, online at www.virtualshareholdermeeting.com/OPLN2026
• ·Board composition: 33% women nominees, 67% born outside U.S., 56% age 58 or under, average tenure 6 years, 2 new nominees in past 2 years
• ·All Board committees comprised of independent directors; independent Chair
• ·Stock ownership: non-employee directors 5x annual retainer (hold 3 years post-vest); CEO 6x base salary, others 3x (hold 60% net shares until met)
• ·Prohibitions: hedging, pledging, repricing options, golden parachute gross-ups, excessive perqs

24-04-2026

Sana Biotechnology, Inc.'s DEF 14A proxy statement nominates Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D. for election as Class II directors at the 2026 Annual Meeting, to serve staggered three-year terms until 2029; all are current directors with extensive biotech experience. The Board consists of nine directors across three classes, with no reported changes or controversies. Deadlines for 2027 stockholder proposals are December 25, 2026 (Rule 14a-8), and director nominations must be submitted between February 4 and March 6, 2027.

• ·Voting results to be filed on Form 8-K no later than June 10, 2026.
• ·Directors elected by plurality vote; no cumulative voting.
• ·Board nominees have served since 2018 (Bishop, Nelsen), 2020 (Reicin).
• ·Dr. Harr reclassified to Class III in April 2026, term expires 2027.

24-04-2026

Vertiv Holdings Co's DEF 14A proxy statement for the 2026 annual shareholder meeting seeks approval for electing 11 directors for a one-year term, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. The board recommends voting FOR all proposals, with the virtual meeting scheduled online starting at 11 a.m. Eastern Time. As of the April 20, 2026 record date, 384,108,816 shares of Class A common stock are outstanding.

• ·Annual meeting held virtually at www.virtualshareholdermeeting.com/VRT2026; check-in opens at 10:45 a.m. Eastern Time.
• ·Record date: April 20, 2026; stockholder voting methods include internet (www.proxyvote.com), telephone (1-800-690-6903), mail, or online during meeting with 16-digit control number.
• ·Proposals require plurality for directors, majority of votes cast for Say-on-Pay and auditor ratification; abstentions and broker non-votes do not count as votes cast.

24-04-2026

Wheels Up Experience Inc. has issued a definitive proxy statement for its 2026 Annual Meeting of Stockholders on June 9, 2026, held virtually, seeking approval for electing four Class II directors to serve until 2029, an advisory vote on named executive officer compensation for FY 2025, ratification of Grant Thornton LLP as independent auditors for FY 2026, and an amendment to the 2021 Long-Term Incentive Plan to increase available Common Stock shares and extend the plan to March 31, 2036. The record date is April 10, 2026, with 724,574,010 shares of Common Stock issued and outstanding, of which 591,214,182 are entitled to vote. The Board recommends voting 'FOR' all proposals; no financial performance metrics or period comparisons are detailed in the filing.

• ·Annual Meeting voting deadline: 11:59 p.m. ET on June 8, 2026
• ·Reverse stock split announced April 14, 2026, expected effective after NYSE close on April 24, 2026 (share counts pre-split)
• ·Meeting quorum requires holders of majority voting power present or by proxy via remote communication

24-04-2026

Perpetua Resources Corp. has issued a proxy statement for its 2026 Annual General Meeting on June 4, 2026 (virtual format), seeking shareholder approval to receive 2025 audited financials, set the board at nine directors, elect nine director nominees, approve the 2026 Equity Incentive Plan, and ratify PricewaterhouseCoopers LLP as auditors for 2026. The record date is April 8, 2026, with 125,093,670 common shares outstanding requiring a quorum of at least 41,697,890 votes. No financial performance metrics, growth, declines, or period comparisons are detailed in the filing.

• ·Annual Meeting at 10:00 a.m. Mountain Time, virtual only at www.virtualshareholdermeeting.com/PPTA2026
• ·Principal office: 405 S. 8th Street, Ste 201, Boise, Idaho 83702
• ·Proxy materials available online via Notice of Internet Availability starting April 24, 2026; 2025 Annual Report on Form 10-K referenced

24-04-2026

Aspira Women’s Health Inc. filed its DEF 14A definitive proxy statement on April 24, 2026, for the Annual Meeting on June 17, 2026, proposing the election of six directors, an advisory vote to approve Named Executive Officer compensation, an amendment to the 2019 Stock Incentive Plan, and ratification of BDO USA, P.C. as independent auditors for the year ending December 31, 2026. The record date is April 20, 2026, with 43,500,411 shares of common stock outstanding. No financial performance metrics or period-over-period comparisons are disclosed in the filing.

• ·Annual Meeting location: offices of Winston & Strawn LLP, 800 Capitol Street, Suite 2400, Houston, TX 77002 at 8:00 a.m. Central Time
• ·Proxy materials and Annual Report on Form 10-K for year ended December 31, 2025 available at www.aspirawh.com or www.proxyvote.com
• ·Notice of Internet Availability of Proxy Materials to be mailed on or about May 8, 2026

24-04-2026

Rumble Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 11, 2026 at 10:00 a.m. ET. Stockholders of record as of April 16, 2026 will vote on electing six director nominees to serve until the 2027 annual meeting and ratifying Baker Tilly US, LLP as independent auditors for the fiscal year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Annual Meeting accessible via virtualshareholdermeeting.com/RUM2026; requires 16-digit control number.
• ·Proxy materials and 2025 Annual Report available at proxyvote.com.
• ·Business Combination closed September 16, 2022; Legacy Rumble renamed Rumble Canada Inc.

24-04-2026

Mobileye Global Inc. (MBLY) has issued its DEF 14A Proxy Statement for the 2026 Annual Stockholders’ Meeting, soliciting votes for the election of 9 director nominees, including CEO Amnon Shashua, Chair Safroadu Yeboah-Amankwah, and 4 independent directors; all current directors are nominees following recent changes such as new appointments in 2025 and the resignation of Christoph Schell effective June 30, 2025. Additional proposals include ratification of the independent registered public accounting firm and an advisory vote to approve executive compensation. The proxy materials were made available to stockholders on April 24, 2026.

• ·Christoph Schell resigned as a director effective June 30, 2025.
• ·Safroadu Yeboah-Amankwah has served as Chair since January 2025.
• ·Patrick Bombach joined as director on January 29, 2025.
• ·Elaine L. Chao joined as director on June 7, 2024.
• ·Naga Chandrasekaran and David Zinsner joined as directors on August 25, 2025.
• ·Director election requires plurality of votes cast; terms run until next annual meeting.

24-04-2026

Watsco's DEF 14A proxy statement details the board leadership structure led by Chairman & CEO Albert H. Nahmad since 1972, emphasizing strong long-term compounded annual TSR outperforming the S&P 500 over 35 years (18.2% vs. 11.2%), 30 years (16.2% vs. 10.4%), 25 years (17.8% vs. 8.8%), 20 years (12.7% vs. 11.0%), and 15 years (15.6% vs. 14.1%). However, the 10-year TSR of 14.6% slightly underperformed the S&P 500's 14.8%. The filing outlines succession planning with A.J. Nahmad as named successor, a Lead Independent Director role held by Mr. Custer, and robust enterprise risk oversight including an annual Enterprise Risk Assessment process.

• ·Co-Vice Chairmen preside at Board meetings when Chairman absent and support succession readiness.
• ·Lead Independent Director duties include advising on Board meetings, shareholder communication, and annual self-evaluation.
• ·Audit Committee oversees enterprise risk assessment, financial reporting risks, cybersecurity, and compliance.
• ·Annual cybersecurity updates to Audit Committee and employee testing program for cyber policy compliance.

24-04-2026

Innodata Inc. filed its definitive proxy statement for the virtual-only 2026 Annual Meeting of Stockholders on June 4, 2026, seeking approval to elect five directors (Jack S. Abuhoff, Daniel H. (Don) Callahan, Richard D. Clarke, Louise C. Forlenza, and Stewart R. Massey), ratify BDO India Services Private Limited as auditors for the year ending December 31, 2026, approve named executive officer compensation on an advisory basis, and approve the Amended and Restated Innodata Inc. Equity Compensation Plan. The Record Date is April 8, 2026, with 32,655,008 shares of Common Stock outstanding. The Board of Directors holds voting authority for 1,246,620 shares, representing approximately 3.8% of total votes.

• ·Meeting held virtually at www.virtualshareholdermeeting.com/INOD2026 at 5:00 p.m. Eastern Time.
• ·Proxy materials available at http://materials.proxyvote.com/457642.
• ·Proposals 1, 3, and 4 considered non-routine (broker non-votes possible); Proposal 2 routine.
• ·Quorum requires majority of outstanding shares.

24-04-2026

nLIGHT, Inc. issued its 2026 Proxy Statement for the virtual Annual Meeting on June 5, 2026, seeking stockholder approval to elect one Class II director nominee, ratify KPMG LLP as independent auditors for FY2026, and approve executive compensation on an advisory basis. The CEO letter highlights strong FY2025 performance with revenue of $261M (+32% YoY), record aerospace and defense revenue of $175M (+60% YoY), gross margins expanding to 30% from 17%, and operating cash flow of $21M versus negative $2.4M in 2024. The company reports a $162M funded backlog and raised $200M via a follow-on offering to support growth in directed energy, laser sensing, and advanced manufacturing.

• ·Annual Meeting record date: April 6, 2026
• ·Proposals: Elect one Class II director to serve until 2029 annual meeting; Ratify KPMG for FY2026; Advisory vote on NEO compensation

24-04-2026

Figure Technology Solutions, Inc. (FIGR) filed a definitive proxy statement (DEF 14A) on April 24, 2026, for its virtual Annual Meeting of Stockholders on June 4, 2026, with a record date of April 9, 2026. Shareholders will vote on electing eight directors (Michael Tannenbaum, Adam Boyden, Michael Cagney, David Katsujin Chao, Lesley Goldwasser, Sachin Jaitly, Daniel Morehead, and June Ou) to serve until the 2027 meeting and ratifying KPMG LLP as independent auditors for the fiscal year ending December 31, 2026. As of the record date, there were 690,250 shares of Blockchain common stock (0.12% voting power), 181,663,016 shares of Class A common stock (32.37% voting power), and 37,893,047 shares of Class B common stock (67.51% voting power outstanding).

• ·Annual Meeting is virtual via live webcast at www.virtualshareholdermeeting.com/FIGR2026; requires 16-digit control number.
• ·Blockchain common stock and Class A common stock: 1 vote per share; Class B common stock: 10 votes per share.
• ·Company address: 100 West Liberty Street, Suite 600, Reno, Nevada 89501.
• ·Proxy materials and 2025 Annual Report available at http://www.proxyvote.com/PROPOSALS.

24-04-2026

Immunome Inc.'s 2025 proxy statement discloses executive compensation for Named Executive Officers, including base salaries of $735,000 for CEO Clay Siegall (5% YoY increase), $472,500 for CFO Max Rosett, and $530,300 for CMO Robert Lechleider. Annual non-equity incentives exceeded targets, with payouts of $661,500 (150% of target) to Siegall, $278,800 (148%) to Rosett, and $307,600 (145%) to Lechleider, driven by exceeding goals in development (60% weighting), research (15%), and stretch objectives, while achieving targets in operations, business development, and commercial areas. New 2025 equity grants included 800,000 stock options to Siegall, 207,000 to Rosett, and 242,000 to Lechleider at $10.60 exercise price.

• ·401(k) plan allows contributions up to $23,500 in 2025 with 100% company match on first 3% of compensation.
• ·Target bonus percentages: 60% of base for Siegall, 40% for Rosett and Lechleider.
• ·Corporate performance categories achieved or exceeded: Development/CMC (60%, exceeded), Research (15%, exceeded), Operations/Finance/Admin (12.5%, achieved), Business Development (7.5%, achieved), Commercial (5%, achieved), Stretch Goals (exceeded).

24-04-2026

Greenlight Capital Re, Ltd. (GLRE) has issued a proxy statement for its Annual General Meeting on July 28, 2026, seeking shareholder approval to elect 11 directors to serve until the 2027 meeting, ratify Deloitte Ltd. as independent auditors for the fiscal year ending December 31, 2026, and conduct a non-binding advisory vote on 2025 named executive officer compensation. The record date for voting eligibility is May 1, 2026, with proxy materials available online at www.envisionreports.com/GLRE. No specific financial performance metrics or period-over-period comparisons are detailed in the provided filing excerpt.

• ·Annual General Meeting location: 65 Market Street, Suite 1207, Jasmine Court, Camana Bay, Grand Cayman, Cayman Islands at 9:00 a.m. local time on July 28, 2026.
• ·Record date for shareholder voting eligibility: close of business on May 1, 2026.
• ·Proxy materials first provided to shareholders on or about May 13, 2026.
• ·Includes disclosures on director compensation, executive compensation tables for fiscal year 2025, pay versus performance, and common share ownership by directors and executives.

24-04-2026

Block, Inc.'s 2026 proxy statement details the virtual annual meeting on June 16, 2026, including election of four Class II directors (Roelof Botha, Amy Brooks, Shawn Carter, James McKelvey), advisory approval of named executive officer compensation (97% support in 2025), ratification of Ernst & Young LLP as auditors, and a stockholder proposal for a board-level technology committee (board recommends against). Governance highlights feature 6 out of 10 independent directors, a lead independent director, and comprehensive clawback policies with no notable declines in board composition metrics. Jack Dorsey receives only a symbolic annual salary of $2.75.

• ·Record date: April 20, 2026 (U.S. Eastern Time)
• ·Annual meeting: June 16, 2026 at 12:00 p.m. PT, virtual at www.virtualshareholdermeeting.com/XYZ2026
• ·Board recommends FOR Proposals 1-3 and AGAINST Proposal 4
• ·All board committees are 100% independent

24-04-2026

10x Genomics, Inc. (TXG) filed its DEF 14A proxy statement on April 24, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 4, 2026, at 11:30 a.m. PDT. Stockholders will vote on electing Class I directors for a three-year term, ratifying Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, and an advisory approval of named executive officer compensation. As of the record date April 8, 2026, there were 118,912,062 shares of Class A common stock (1 vote each) and 10,078,872 shares of Class B common stock (10 votes each) outstanding.

• ·Annual Meeting conducted exclusively online via live webcast at https://edge.media-server.com/mmc/p/e4koppar
• ·Proxy materials available at http://www.astproxyportal.com/ast/23039, including Annual Report on Form 10-K for year ended December 31, 2025

24-04-2026

Applied Optoelectronics, Inc. (AAOI) has issued its 2026 Proxy Statement for the Annual Meeting on June 4, 2026, proposing the election of two Class I directors (Che-Wei Lin and Robert Flanagan), ratification of Grant Thornton LLP as independent auditors for fiscal year ending December 31, 2026, advisory approval of named executive officer compensation, amendment to the Certificate of Incorporation to clarify voting standards for certain future amendments, approval of the 2026 Equity Incentive Plan, and an adjournment proposal if needed; the Board recommends voting FOR all items. The company highlights its market cap of $11.7B, 4,800 employees across 3 countries, and monthly manufacturing capacity exceeding 1.2M semiconductor chips, 270K optical transceivers, and 75 amplifiers. Governance features include an independent compensation committee, no hedging/pledging, clawback policy, and stock ownership guidelines.

• ·Annual Meeting location: 13139 Jess Pirtle Blvd., Sugar Land, TX 77478 at 9:30 a.m. Central Time
• ·Over 300 end customers in 38 countries
• ·500+ employees in Texas
• ·Publicly traded on Nasdaq under AAOI
• ·Founded in 1997

24-04-2026

Aimco's definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be held on June 10, 2026, at 9:30 am MT in Denver, CO, seeks stockholder approval to elect nine directors for one-year terms, ratify Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and conduct an advisory vote to approve executive compensation. The record date for voting is April 22, 2026, with proxy materials furnished electronically. As of December 31, 2025, Aimco owns 94.1% of the legal interest and 96.6% of the economic interest in Aimco Operating Partnership, following the 2020 Separation that created Apartment Income REIT Corp. (AIR).

• ·Annual Meeting location: 4582 South Ulster Street, Suite 1450, Denver, CO 80237.
• ·Proxy materials and 2025 Annual Report available at www.edocumentview.com/AIV or SEC website.
• ·Aimco is a self-administered REIT and general partner of Aimco Operating Partnership.

24-04-2026

Outset Medical, Inc. filed its DEF 14A definitive proxy statement dated April 24, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026 at 1:30 p.m. Pacific Time. Stockholders of record as of April 9, 2026, will vote on electing two Class III directors to serve until the 2029 annual meeting, a non-binding advisory vote to approve 2025 named executive officer compensation as disclosed, and ratification of KPMG LLP as the independent registered public accounting firm for 2026. The proxy includes sections on board governance, director nominees, executive compensation discussion and analysis, and pay versus performance disclosures.

• ·Record date: Close of business on April 9, 2026
• ·Virtual meeting access: www.virtualshareholdermeeting.com/OM2026
• ·Proxy materials available at https://investors.outsetmedical.com/financial-information/annual-reports and www.proxyvote.com
• ·References 2025 Summary Compensation Table, Grants of Plan-Based Awards in 2025, and Outstanding Equity Awards at 2025 Year-End (no specific values disclosed in filing excerpt)

24-04-2026

Lyell Immunopharma, Inc. issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026 at 8:00 a.m. PT, with a record date of April 14, 2026. Stockholders are asked to vote on electing three Class II directors for three-year terms, ratifying Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and approving on an advisory basis the compensation of named executive officers. As of the record date, 23,332,524 shares of common stock were outstanding and entitled to vote.

• ·Annual Meeting accessible via live webcast at www.virtualshareholdermeeting.com/LYEL2026; login starts at 7:45 a.m. PT.
• ·Proxy materials notice mailed on or about April 24, 2026.
• ·Voting standards: Plurality for director election; majority of votes cast (excluding abstentions and broker non-votes) for Proposals 2 and 3.

24-04-2026

Lifetime Brands, Inc. (LCUT) filed its DEF 14A Proxy Statement on April 24, 2026, proposing the election of nine directors, including current Chairman Jeffrey Siegel, CEO Robert B. Kay, and new nominee Daniel Siegel, at the 2026 Annual Meeting. As of April 17, 2026, directors and executive officers as a group beneficially own 10,356,870 shares or 44.4% of the 22,855,008 outstanding common shares, led by Bruce G. Pollack at 6,087,456 shares (26.6%) linked to Centre Partners V, L.P.'s 5,993,116 shares (26.2%). The company retained proxy solicitor Georgeson at an anticipated cost of $10,500 plus expenses.

• ·Other individual director/executive ownership as of April 17, 2026: Jeffrey Siegel (1,244,038 shares, 5.4%), Robert B. Kay (1,223,291 shares, 5.3%), Craig Phillips (645,293 shares, 2.8%), Daniel Siegel (480,340 shares, 2.1%).
• ·Director nominees include current directors except for Daniel Siegel.
• ·Filament Acquisition closed March 1, 2018; related Stockholders Agreement required appointment of three Taylor Parent designees (Kay, Pollack, Schnabel).

24-04-2026

Harrow, Inc. (HROW) filed a DEF 14A Proxy Statement on April 24, 2026, for its 2026 Annual Meeting of Stockholders scheduled for June 18, 2026, at 8:00 a.m. CT at its Nashville, TN office. The filing includes XBRL-tagged disclosures on Pay vs. Performance for the Principal Executive Officer and Non-PEO Named Executive Officers covering fiscal years 2021-2025, encompassing metrics such as aggregate stock/option award values, fair values at year-end, year-over-year changes, vesting date values, and dividends on unvested awards. Stockholders are notified of internet availability of proxy materials and the Annual Report for the year ended December 31, 2025, filed on March 2, 2026.

• ·Annual Meeting location: 1A Burton Hills Blvd., Suite 200, Nashville, TN 37215.
• ·Proxy materials available via Notice of Internet Availability; paper copies available upon request.

24-04-2026

Eton Pharmaceuticals, Inc. (ETON) filed a DEF 14A proxy statement dated April 24, 2026, for its 2026 Annual Meeting of Stockholders on June 9, 2026, seeking approval for the reelection of directors Jenn Adams and Charles J. Casamento to three-year terms and ratification of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. As of the record date of April 10, 2026, 27,359,791 shares of common stock were outstanding, with a quorum requiring a majority present in person or by proxy. No financial performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Annual Meeting time and format: 10:00 a.m. CDT virtually at meetnow.global/M7JY67S.
• ·Proxy voting cutoff: 11:59 p.m. central time on June 8, 2026 for telephone/Internet; mail must be received before meeting start.
• ·Voting requirements: Plurality for director election; majority of votes cast for auditor ratification.
• ·Proxy materials and 2025 Form 10-K available at www.envisionreports.com/ETON.

24-04-2026

Rigetti Computing, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders on June 9, 2026, at 9:00 A.M. Pacific Time, virtually, to elect Dr. Subodh Kulkarni as the sole Class I director until the 2029 Annual Meeting and to ratify BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The Record Date is April 15, 2026, with 332,345,548 shares of common stock outstanding entitled to vote. No other matters are anticipated, and the Board recommends voting 'FOR' both proposals.

• ·Annual Meeting accessible virtually at www.virtualshareholdermeeting.com/RGTI2026; requires 16-digit control number.
• ·Proxy voting deadline: 8:59 p.m. Pacific Time on June 8, 2026.
• ·Stockholder list available for examination at headquarters (775 Heinz Avenue, Berkeley, CA 94710) for 10 days ending day prior to meeting, upon written request to IR@rigetti.com.

24-04-2026

Willis Lease Finance Corp (WLFC) filed its DEF 14A proxy statement for the 2026 Annual Meeting, seeking shareholder approval on five proposals: election of a Class I director nominee (plurality vote), amendment to the Certificate of Incorporation for a forward stock split and increase in authorized Common and Preferred Stock shares (requiring 80% of outstanding shares), advisory vote on named executive officer compensation, ratification of the independent auditor, and potential adjournment to solicit more votes for Proposal 2. The record date is April 6, 2026, with 7,604,821 shares of Common Stock outstanding, and a majority quorum required. The Board recommends voting FOR all proposals; no financial performance metrics or period comparisons are detailed in the filing.

• ·Voting deadlines: proxies via internet/telephone by 11:59 p.m. ET on May 25, 2026; beneficial holders registering for virtual meeting voting by 5:00 p.m. ET on May 25, 2026.
• ·Proposal 1 (director election): plurality standard, non-routine (no broker discretion).
• ·Proposal 2: routine (broker discretion permitted), abstentions count as AGAINST.
• ·Proposals 3,4,5: majority of votes present, non-routine except Proposal 4 (routine with broker discretion).
• ·Broker non-votes count for quorum but not for approval; abstentions/withholds impact as noted.

24-04-2026

Comcast reported robust 2025 consolidated financial results with revenue of $123.7 billion, net income of $20.0 billion, and Adjusted EBITDA of $37.4 billion, while returning $11.7 billion to shareholders via $6.8 billion in share repurchases and $4.9 billion in dividends, reducing shares outstanding by 5%. Key segments showed growth including connectivity revenue up 4.2% to $46.0 billion, Peacock revenue increasing 10% to $5.4 billion with paid subscribers up 22% to 44 million and Adjusted EBITDA losses improved by nearly $700 million, and theme parks Adjusted EBITDA of $3.1 billion; business services revenue reached $10.2 billion. The company completed the tax-free spin-off of Versant Media Group in January 2026 and announced leadership changes with Mike Cavanagh promoted to Co-CEO and Gordon Smith joining the Board.

• ·Domestic wireless achieved 1.5 million net line additions in 2025, surpassing 15% penetration of domestic residential broadband customers.
• ·Comcast generated highest free cash flow in company history in 2025.

24-04-2026

OneSpaWorld Holdings Limited (OSW) filed a DEF 14A proxy statement dated April 24, 2026, for its 2026 Annual Meeting of Shareholders on June 3, 2026, in Nassau, Bahamas, with a record date of April 8, 2026. Shareholders will vote on election of directors, say-on-pay advisory vote, approval of the Amended and Restated 2019 Equity Incentive Plan, and ratification of the independent registered public accounting firm. The filing includes Compensation Discussion and Analysis, director compensation details, and XBRL-tagged executive compensation data for Principal Executive Officer Leonard Fluxman and others, with references to fiscal years 2021 through 2025.

• ·Annual Meeting location: Library Room, The Island House, Mahogany Hill, Western Road, Nassau, Bahamas at 11:00 a.m. Eastern Daylight Time.
• ·Proxy materials available at www.proxyvote.com; paper copies requestable by May 20, 2026.
• ·Forward-looking statements caution regarding risks including economic factors, competition, and potential outbreaks impacting cruise spa services.

24-04-2026

Arcturus Therapeutics Holdings Inc. (ARCT) filed a definitive proxy statement (DEF 14A) on April 24, 2026, for its 2026 Annual Meeting of Stockholders, to be held virtually on June 5, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 14, 2026 (with 28,423,069 shares of common stock outstanding) are asked to vote on: (1) election of eight directors (Dr. Peter Farrell, Joseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John H. Markels, Dr. Moncef Slaoui); (2) non-binding advisory approval of named executive officer compensation; and (3) ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board recommends voting 'FOR' all proposals; no other matters are anticipated.

• ·Annual Meeting is completely virtual at https://www.cstproxy.com/arcturusrx/2026; preregistration recommended using control number.
• ·Internet voting available until 11:59 p.m. Eastern Time on June 4, 2026.
• ·No cumulative voting rights for director election.

24-04-2026

Fractyl Health, Inc. (GUTS) has filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, at 12:00 p.m. ET, with proposals to elect Marc Elia, Clive Meanwell, M.B., Ch.B., M.D., and Ian Sheffield as Class II directors for three-year terms and to ratify Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is April 17, 2026, with 158,648,963 shares of common stock outstanding entitled to vote. No financial performance metrics or period comparisons are discussed.

• ·Annual Meeting accessible virtually at www.virtualshareholdermeeting.com/GUTS2026 using 16-digit control number
• ·Proxy materials and Annual Report available at www.proxyvote.com
• ·Stockholders of record as of April 17, 2026 entitled to vote; one vote per share

24-04-2026

Kodiak AI, Inc., formed via a Business Combination with Ares Acquisition Corporation II on September 24, 2025, is soliciting proxies for its 2026 annual stockholder meeting on June 11, 2026, at 10:00 a.m. PT virtually via www.virtualshareholdermeeting.com/KDK2026. Stockholders of record as of April 17, 2026, will vote on electing two Class I directors to serve until the 2029 annual meeting and ratifying Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. As of the record date, 183,804,469 shares of Common Stock and 142,155 shares of Series A Preferred Stock (each with 104 as-converted votes) are outstanding.

• ·Business Combination closed September 24, 2025; Legacy Kodiak stockholders received 85.5% of post-combination common and preferred stock on as-converted basis
• ·Proxy materials available at www.proxyvote.com as of April 24, 2026
• ·No other matters known to management as of proxy statement date

24-04-2026

IRIDEX Corporation's definitive proxy statement for the 2026 Annual Meeting of Stockholders on June 12, 2026, at 8:00 a.m. PT proposes electing five directors (Proposal One), ratifying BPM LLP as independent registered public accounting firm for fiscal year 2026 ending January 2, 2027 (Proposal Two), and an advisory vote to approve named executive officer compensation (Proposal Three). The record date for voting eligibility is April 17, 2026, with proxy materials available online at www.proxyvote.com. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting location: 1212 Terra Bella Avenue, Mountain View, California 94043.
• ·Internet Notice mailed on or about May 1, 2026.
• ·Fiscal year end: January 3 (e.g., FY2025 ended January 3, 2026; FY2026 ends January 2, 2027).
• ·Contact for directions: Investor Relations at (650) 940-4700 or investors@iridex.com.

24-04-2026

Globus Medical, Inc. issued its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders on June 3, 2026, at 6:00 p.m. ET at its headquarters in Audubon, PA, with a record date of April 13, 2026. Key proposals include electing two Class II directors to serve until the 2029 Annual Meeting, approving an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 1,000,000, ratifying Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026, and a non-binding advisory vote on named executive officer compensation. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting location: Valley Forge Business Center, 2560 General Armistead Avenue, Audubon, PA 19403
• ·Proxy materials available electronically starting April 24, 2026

24-04-2026

Fate Therapeutics Inc.'s DEF 14A proxy statement, filed April 24, 2026, solicits votes for the 2026 Annual Meeting on electing three Class I directors, ratifying Ernst & Young LLP as auditors for fiscal year ending December 31, 2026, advisory approval of named executive officer compensation, and amending the 2022 Stock Option and Incentive Plan to increase reserved shares by 7,000,000. Record date is April 15, 2026, with 116,281,693 common shares outstanding; voting deadline is June 11, 2026. No performance metrics or period comparisons are detailed in the filing.

• ·Proposals 1, 3, and 4 are non-routine (broker non-votes possible); Proposal 2 is routine.
• ·Quorum requires majority of outstanding shares present or by proxy.
• ·Proxy materials accessible at www.proxydocs.com/FATE; Notice mailed on or about April 24, 2026.

24-04-2026

Regeneron Pharmaceuticals, Inc. filed its 2026 definitive proxy statement ahead of its June 12, 2026 annual shareholder meeting, highlighting strong 2025 financial performance with $14.3B in revenues from blockbuster products including Dupixent ($17.8B global sales by Sanofi), retinal franchise ($7.9B global sales), and Libtayo ($1.5B global sales). The company invested $5.9B in R&D (41% of revenues), committed $9B to U.S. manufacturing/R&D expansion, and returned $3.8B to shareholders, while advancing nearly 50 clinical candidates powered by proprietary technologies.

• ·Annual shareholder meeting scheduled for June 12, 2026
• ·15 approved or authorized medicines since inception, averaging nearly one new product launch per year over past 15 years

24-04-2026

Arlo Technologies reported exceptional 2025 financial results, including Annual Recurring Revenue over $330 million (up 28% from 2024), Subscriptions and Services Revenue over $316 million (up 30% from 2024, representing 60% of total revenue), and Adjusted EBITDA of $75 million (up 85% from 2024), driving a total shareholder return of nearly 300% since 2022. Cumulative Paid Accounts reached 5.7 million (up 24% from 2024), with Net Income of $15 million and Free Cash Flow of $67 million (up 38% from 2024). The 2026 Annual Meeting on June 18, 2026, seeks stockholder approval for electing three Class II directors, ratifying Deloitte & Touche LLP as auditors for fiscal year ending December 31, 2026, and an advisory vote on executive compensation.

• ·Annual Meeting record date: April 20, 2026; virtual at http://www.virtualshareholdermeeting.com/ARLO2026.
• ·Board recommends FOR all three proposals: election of three Class II directors for three-year terms until 2029, ratification of auditors, advisory approval of NEO compensation.
• ·Robust governance: independent Chair, all committees independent, average board tenure 6 years, stock ownership guidelines (CEO 6x base pay, others 3x, directors 5x retainer), proxy access bylaws.
• ·EPS $0.14; Non-GAAP Diluted EPS $0.70 (up 75% YoY).

24-04-2026

Interactive Strength Inc. (TRNR) has issued a proxy statement for its 2026 Annual Meeting on June 4, 2026, seeking shareholder approval for electing two Class III directors, ratifying Deloitte & Touche LLP as auditors, approving significant share issuances exceeding 20% of outstanding common stock for the Wattbike acquisition (Series E Preferred) and Ergatta merger (Series D Preferred), amending the 2023 Stock Incentive Plan, authorizing a reverse stock split (1-for-4 to 1-for-100), and advisory votes on executive compensation. These proposals include potentially dilutive equity issuances and a reverse split, signaling efforts to complete acquisitions and manage share price compliance amid low outstanding shares of 2,057,018 as of the April 8, 2026 record date. No financial performance metrics are detailed in the filing.

• ·Annual Meeting location: 1005 Congress Ave, Suite 925, Austin, Texas 78701 at 10 a.m. Eastern Time.
• ·Prior 1-for-10 reverse stock split effective February 23, 2026.
• ·Record date registration deadline for beneficial owners: May 22, 2026.

24-04-2026

Columbia Sportswear Company's 2026 Proxy Statement outlines the virtual Annual Meeting on June 10, 2026, to elect ten directors, ratify Deloitte & Touche LLP as auditors, approve executive compensation on a non-binding basis, approve the Amended and Restated 2020 Stock Incentive Plan, and consider a shareholder proxy access proposal. Fiscal 2025 results showed net sales of $3.40 billion (+1% YoY) and gross margin expansion to 50.5% (+30 bps), but operating income declined 24% to $207.0 million and diluted EPS fell 15% to $3.24. The company returned $66 million in dividends and repurchased $201 million in shares amid the Columbia ACCELERATE Growth Strategy.

• ·Annual Meeting record date: April 6, 2026
• ·Nine of ten Board directors are independent
• ·Products sold in 115 countries
• ·Board nominees: Boyle, Babson, Bryant, Culver, Denson, Mansell, Nelson, Shi, Simmons, Wasson

24-04-2026

Caribou Biosciences, Inc. (CRBU) has filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on June 17, 2026, at 7:30 a.m. PDT, held virtually at www.virtualshareholdermeeting.com/CRBU2026. Key proposals include electing three Class II directors—Andrew Guggenhime, M.B.A., David Johnson, M.B.A., and Nancy Whiting, Pharm.D.—to serve until the 2029 annual meeting; ratifying Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026; and approving an amendment to the certificate of incorporation for officer exculpation from certain fiduciary duties. The record date is April 20, 2026, with 98,682,370 shares of common stock outstanding, and proxy materials were made available on April 24, 2026.

• ·Record date: Close of business on April 20, 2026
• ·Voting methods: Internet (www.proxyvote.com), telephone (1-800-690-6903), mail, or virtually at the meeting (deadline 11:59 p.m. EDT on June 16, 2026)
• ·Company address: 2929 7th Street, Suite 105, Berkeley, CA 94710
• ·References 2025 Annual Report on Form 10-K for year ended December 31, 2025, available at www.proxyvote.com or SEC website

24-04-2026

Agios Pharmaceuticals, Inc.'s DEF 14A proxy statement, filed April 24, 2026, discloses beneficial ownership of common stock as of March 31, 2026, with 59,341,338 shares outstanding. Major 5%+ stockholders include The Vanguard Group (9.4%), Farallon Capital affiliates (8.7%), BlackRock (7.6%), State Street (5.2%), and Armistice Capital (5.1%), while directors and executive officers as a group beneficially own 5.4%. The filing includes standard proxy information for the annual meeting, stockholder proposal procedures for 2027, and forward-looking statements on products like PYRUKYND and pipeline candidates.

• ·Ownership calculated including shares subject to options exercisable within 60 days of March 31, 2026.
• ·Stockholder proposals for 2027 annual meeting must be submitted to corporate secretary per bylaws and SEC rules.
• ·Annual Report on Form 10-K for year ended December 31, 2025 available via Investor Relations.